Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Motion sickness (adults) renalcarematters.com, reviewed
Kidney dosing: Cinnarizine (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- Motion sickness: 30 mg 2 hours before travel, then 15 mg every 8 hours during the journey (SmPC).
- CrCl 30–59 mL/min
- No specific studies in kidney impairment; the SmPC says to use with care. Use with caution and specialist judgment.
- CrCl 15–29 mL/min
- No specific studies in kidney impairment; the SmPC says to use with care. Use with caution and specialist judgment.
- CrCl <15 mL/min (not on dialysis)
- No specific studies in kidney impairment; the SmPC says to use with care. Use with caution and specialist judgment.
- Hemodialysis (intermittent)
- Not studied in dialysis; no dose given.
- Peritoneal dialysis
- Not studied in dialysis; no dose given.
- CRRT
- Not studied in dialysis; no dose given.
- Dialyzable? Not stated (91% protein-bound).
- Monitoring Sedation (worse with alcohol and central nervous system depressants); extrapyramidal symptoms and parkinsonism, especially in older adults on long-term use (SmPC 4.4, 4.8).
From the Cinnarizine monograph (renalcarematters.com, reviewed).
Use: Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Tablet: 40 mg/20 mg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Cinnarizine + Dimenhydrinate as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
DimezineDimenhydrinate + Cinnarizine | 40mg/20mg TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc. | DR-XY43105 | Dec 19, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .